Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.34 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 2/20 | 0.31 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28168096 | 0.90 | EPHX1 (0.44) | EPHX1ALDH1A1GPR35SMN1; SMN2NAAA | |
| SCHEMBL27595620 | 0.90 | EPHX1 (0.48) | EPHX1GPR35SMN1; SMN2NAAACYP19A1 | |
| SCHEMBL1584701 | 0.88 | EPHX1 (0.52) | EPHX1ALDH1A1GPR35SMN1; SMN2NAAA | |
| SCHEMBL4674791 | 0.78 | — | — | |
| SCHEMBL697519 | 0.76 | — | — | |
| SCHEMBL28281707 | 0.76 | — | — | |
| SCHEMBL1078014 | 0.76 | EPHX1 (0.39) | EPHX1ALDH1A1SERPINE1SMN1; SMN2NAAA | |
| SCHEMBL27799400 | 0.75 | MAPT (0.43) | EPHX1ALDH1A1GAANAAAEGLN1 | |
| SCHEMBL11591531 | 0.75 | EPHX1 (0.50) | EPHX1GPR35NAAACYP19A1 | |
| SCHEMBL5548750 | 0.74 | EPHX1 (0.42) | EPHX1GPR35SERPINE1SMN1; SMN2NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111440119-A | Preparation method of cabozantinib intermediate | 郑州大学第一附属医院 | 2020-07-24 | — | — | CN | claimed |
| CN-110143917-B | Preparation method of cabozantinib metabolite | 郑州大学第一附属医院 | 2020-03-31 | — | — | CN | claimed |
| US-11498902-B2 | Process for the preparation of Cabozantinib and its pharmaceutically acceptable salts thereof | NATCO PHARMA LIMITED (IN) | 2022-11-15 | — | — | US | disclosed |
| CN-114173787-A | Dihydropyrimidine derivatives and their use in the treatment of HBV infection or HBV-induced diseases | 杨森科学爱尔兰无限公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-111440119-B | Preparation method of cabozantinib intermediate | 郑州大学第一附属医院 | 2021-08-24 | — | — | CN | disclosed |
| CN-111440119-B | Preparation method of cabozantinib intermediate | 郑州大学第一附属医院 | 2021-08-24 | — | — | CN | disclosed |
| US-20210188776-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF CABOZANTINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | NATCO PHARMA LIMITED (IN) | 2021-06-24 | — | — | US | disclosed |
| EP-3299369-B1 | PYRIDO-AZAHETERECYDIC COMPOUND AND PREPARATION METHOD AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2020-11-11 | — | — | EP | disclosed |
| CN-107709320-B | Pyrido-nitrogen heterocyclic compound and preparation method and application thereof | 中国科学院上海药物研究所 | 2020-11-06 | — | — | CN | disclosed |
| CN-111440119-A | Preparation method of cabozantinib intermediate | 郑州大学第一附属医院 | 2020-07-24 | — | — | CN | disclosed |
| CN-111440119-A | Preparation method of cabozantinib intermediate | 郑州大学第一附属医院 | 2020-07-24 | — | — | CN | disclosed |
| US-10710996-B2 | Pyrido-azaheterecydic compound and preparation method and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-07-14 | — | — | US | disclosed |
| CN-110143917-B | Preparation method of cabozantinib metabolite | 郑州大学第一附属医院 | 2020-03-31 | — | — | CN | disclosed |
| CN-110143917-B | Preparation method of cabozantinib metabolite | 郑州大学第一附属医院 | 2020-03-31 | — | — | CN | disclosed |
| EP-3299369-A1 | PYRIDO-AZAHETERECYDIC COMPOUND AND PREPARATION METHOD AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2018-03-28 | — | — | EP | disclosed |
| CN-107709320-A | A kind of pyrido nitrogen heterocyclic and its production and use | 中国科学院上海药物研究所 | 2018-02-16 | — | — | CN | disclosed |
| CN-106279147-A | A kind of pyrido nitrogen heterocyclic and its production and use | 中国科学院上海药物研究所 | 2017-01-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188776-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF CABOZANTINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | FIP1L1, FGFR1, RCC1 | EPHX1 3360/4885ALDH1A1 316/4885GPR35 3263/4885 |
| US-11498902-B2 | Process for the preparation of Cabozantinib and its pharmaceutically acceptable salts thereof | FIP1L1, ABL1, FGFR1 | EPHX1 3463/4885ALDH1A1 218/4885GPR35 3369/4885 |
| US-10710996-B2 | Pyrido-azaheterecydic compound and preparation method and use thereof | MET, MERTK, DMPK | EPHX1 1936/4885ALDH1A1 2733/4885GPR35 2092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.